Abstract
Despite declining incidence in developed countries, gastric cancer is still the second cause of cancer death worldwide, while proximal gastric cancer is increasing in incidence. Cytotoxic combinations of platinum salts, fluoropyrimidines with or without taxanes or anthracyclines improved response rates but failed to improve the median survival of patients with advanced gastric cancer beyond the 12-month benchmark. Novel rationally designed therapies targeting molecular aberrations which are tumour-specific and pivotal for tumour survival, are urgently needed in order to improve patient outcome. Angiogenic mediators, transmembrane receptors, signal transduction molecules, transcription factors, epigenetic regulators and other biomolecules are among potential targets being modulated by monoclonal antibodies or small molecules in current phase I, II and III clinical trials. To date, only the addition of trastuzumab, an anti-HER2 monoclonal antibody combined with chemotherapy has yielded a clinically meaningful survival improvement in patients with advanced gastric cancer overexpressing HER2.
Keywords: Targeted therapy, gastric cancer, prognosis
Current Medicinal Chemistry
Title: Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Volume: 18 Issue: 11
Author(s): G. Pentheroudakis and A. Stoyianni
Affiliation:
Keywords: Targeted therapy, gastric cancer, prognosis
Abstract: Despite declining incidence in developed countries, gastric cancer is still the second cause of cancer death worldwide, while proximal gastric cancer is increasing in incidence. Cytotoxic combinations of platinum salts, fluoropyrimidines with or without taxanes or anthracyclines improved response rates but failed to improve the median survival of patients with advanced gastric cancer beyond the 12-month benchmark. Novel rationally designed therapies targeting molecular aberrations which are tumour-specific and pivotal for tumour survival, are urgently needed in order to improve patient outcome. Angiogenic mediators, transmembrane receptors, signal transduction molecules, transcription factors, epigenetic regulators and other biomolecules are among potential targets being modulated by monoclonal antibodies or small molecules in current phase I, II and III clinical trials. To date, only the addition of trastuzumab, an anti-HER2 monoclonal antibody combined with chemotherapy has yielded a clinically meaningful survival improvement in patients with advanced gastric cancer overexpressing HER2.
Export Options
About this article
Cite this article as:
Pentheroudakis G. and Stoyianni A., Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer, Current Medicinal Chemistry 2011; 18 (11) . https://dx.doi.org/10.2174/092986711795471365
DOI https://dx.doi.org/10.2174/092986711795471365 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro and In Vivo Transformations of Lutein
Mini-Reviews in Organic Chemistry Preoperative Albumin Level Serves as a Predictor for Postoperative Pulmonary Complications Following Elective Laparoscopic Gastrectomy
Current Pharmaceutical Design Macrocyclic Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Acyclovir Entrapped N-Trimethyl Chitosan Nanoparticles for Oral Bioavailability Enhancement
Current Nanoscience Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
Current Pharmaceutical Biotechnology Detection of Liver Metastases with Contrast Enhanced Ultrasonography
Current Medical Imaging Autophagy and Toxins: A Matter of Life or Death
Current Molecular Medicine Action Mechanisms of Chinese Herbal Compound at the Molecular Level
Letters in Drug Design & Discovery Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Iron Deficiency: The Hidden Miscreant in Inflammatory Bowel Disease
Current Drug Targets New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design The Development of a PBPK Model for Atomoxetine Using Levels in Plasma, Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated Kidney Function
CNS & Neurological Disorders - Drug Targets Inhibition of Calcium Oxalate Nephrotoxicity with Cymbopogon Schoenanthus (Al-Ethkher)
Drug Metabolism Letters PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry